Misplaced Pages

Atumelnant: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactivelyContent deleted Content addedVisualWikitext
Revision as of 06:45, 27 December 2024 editBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,699 edits created drug stubTag: nowiki added  Latest revision as of 23:35, 29 December 2024 edit undoJosve05a (talk | contribs)Autopatrolled, Extended confirmed users, New page reviewers, Pending changes reviewers, Rollbackers154,738 editsm added orphan tagTag: AWB 
(3 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{Orphan|date=December 2024}}

{{cs1 config|name-list-style=vanc|display-authors=6}} {{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug {{Infobox drug
Line 18: Line 20:
| widthR = | widthR =
| altR = | altR =
| captionLR = | captionLR =


<!-- Clinical data --> <!-- Clinical data -->
Line 39: Line 41:
| ATC_prefix = | ATC_prefix =
| ATC_suffix = | ATC_suffix =
| ATC_supplemental = | ATC_supplemental =


<!-- Legal status --> <!-- Legal status -->
Line 60: Line 62:
| legal_UN = | legal_UN =
| legal_UN_comment = | legal_UN_comment =
| legal_status = | legal_status =


<!-- Pharmacokinetic data --> <!-- Pharmacokinetic data -->
Line 70: Line 72:
| elimination_half-life = | elimination_half-life =
| duration_of_action= | duration_of_action=
| excretion = | excretion =


<!-- Identifiers --> <!-- Identifiers -->
Line 109: Line 111:
}} }}


'''Atumelnant''' (CRN04894) is an ] developed by Crinetics Pharmaceuticals for the treatment of ] (ACTH)-dependent endocrine disorders. It is a selective ] of the ] (MC2R), also known as the ACTH receptor, which is primarily expressed in the adrenal glands.<ref>{{cite web | title = Atumelnant (CRN04894) | url = https://crinetics.com/pipeline/atumelnant-cushings-syndrome-cah/ | work = crinetics.com }}</ref> Atumelnant is being evaluated to treat conditions such as ] (CAH) and ACTH-dependent ] caused for example by ].<ref name="Varlamov_2024">{{cite journal | vauthors = Varlamov EV, Gheorghiu ML, Fleseriu M | title = Pharmacological management of pituitary adenomas - what is new on the horizon? | journal = Expert Opinion on Pharmacotherapy | volume = | issue = | pages = | date = December 2024 | pmid = 39718553 | doi = 10.1080/14656566.2024.2446625 }}</ref> '''Atumelnant''' (CRN04894) is an ] developed by Crinetics Pharmaceuticals for the treatment of ] (ACTH)-dependent endocrine disorders. It is a selective ] of the ] (MC2R), also known as the ACTH receptor, which is primarily expressed in the adrenal glands.<ref>{{cite web | title = Atumelnant (CRN04894) | url = https://crinetics.com/pipeline/atumelnant-cushings-syndrome-cah/ | work = crinetics.com | date = 14 August 2020 }}</ref> Atumelnant is being evaluated to treat conditions such as ] (CAH) and ACTH-dependent ] caused for example by ].<ref name="Varlamov_2024">{{cite journal | vauthors = Varlamov EV, Gheorghiu ML, Fleseriu M | title = Pharmacological management of pituitary adenomas - what is new on the horizon? | journal = Expert Opinion on Pharmacotherapy | volume = | issue = | pages = | date = December 2024 | pmid = 39718553 | doi = 10.1080/14656566.2024.2446625 }}</ref>


== References == == References ==
{{reflist}} {{reflist}}


⚫ ]
⚫ {{pharma-stub}}
⚫ ]
] ]
] ]
Line 123: Line 124:
] ]
] ]
]


⚫ {{pharma-stub}}

Latest revision as of 23:35, 29 December 2024

This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2024)

Pharmaceutical compound
Atumelnant
Clinical data
Other namesCRN04894
Identifiers
IUPAC name
  • N-octan-3-yl]-6-(2-ethoxyphenyl)-3-piperazin-1-yl]pyridine-2-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
UNII
Chemical and physical data
FormulaC33H42F3N5O3
Molar mass613.726 g·mol
3D model (JSmol)
SMILES
  • CC1CN(CCN1C2=C(N=C(C=C2)C3=CC=CC=C3OCC)C(=O)N4CN5CCC4CC5)C(=O)C6(CCC6)C(F)(F)F
InChI
  • InChI=InChI=1S/C33H42F3N5O3/c1-3-23-20-40(31(43)32(14-7-15-32)33(34,35)36)18-19-41(23)27-11-10-25(24-8-5-6-9-28(24)44-4-2)37-29(27)30(42)38-26-21-39-16-12-22(26)13-17-39/h5-6,8-11,22-23,26H,3-4,7,12-21H2,1-2H3,(H,38,42)/t23-,26-/m1/s1
  • Key:QJRFBKYETDVAJQ-ZEQKJWHPSA-N

Atumelnant (CRN04894) is an investigational new drug developed by Crinetics Pharmaceuticals for the treatment of adrenocorticotropic hormone (ACTH)-dependent endocrine disorders. It is a selective antagonist of the melanocortin type 2 receptor (MC2R), also known as the ACTH receptor, which is primarily expressed in the adrenal glands. Atumelnant is being evaluated to treat conditions such as congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome caused for example by pituitary adenomas.

References

  1. "Atumelnant (CRN04894)". crinetics.com. 14 August 2020.
  2. Varlamov EV, Gheorghiu ML, Fleseriu M (December 2024). "Pharmacological management of pituitary adenomas - what is new on the horizon?". Expert Opinion on Pharmacotherapy. doi:10.1080/14656566.2024.2446625. PMID 39718553.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: